142 related articles for article (PubMed ID: 38408741)
1. Buprenorphine microdosing regimen using transdermal buprenorphine patches to transition from methadone to buprenorphine.
Naren T; Cook J; MacCartney P; Membrey D
Drug Alcohol Rev; 2024 May; 43(4):1013-1018. PubMed ID: 38408741
[TBL] [Abstract][Full Text] [Related]
2. Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol.
Terasaki D; Smith C; Calcaterra SL
Pharmacotherapy; 2019 Oct; 39(10):1023-1029. PubMed ID: 31348544
[TBL] [Abstract][Full Text] [Related]
3. Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series.
Soyka M; Groß G
Am J Drug Alcohol Abuse; 2021 Sep; 47(5):599-604. PubMed ID: 34407703
[TBL] [Abstract][Full Text] [Related]
4. Methadone to buprenorphine/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting-Azar method.
Azar P; Nikoo M; Miles I
Am J Addict; 2018 Dec; 27(8):601-604. PubMed ID: 30387894
[TBL] [Abstract][Full Text] [Related]
5. Rapid Induction Therapy for Opioid-Use Disorder Using Buprenorphine Transdermal Patch: A Case Series.
Saal D; Lee F
Perm J; 2020; 24():. PubMed ID: 32240088
[TBL] [Abstract][Full Text] [Related]
6. Novel Uses of Methadone Under the "72-Hour Rule" to Facilitate Transitions of Care and Low-Dose Buprenorphine Induction in an Outpatient Bridge Clinic.
Shahlapour M; Singh S; Christine PJ; Laks J; Evans J; Farrell NM; Khan GK; Taylor JL; Rozansky H
J Addict Med; 2024 May-Jun 01; 18(3):345-347. PubMed ID: 38329815
[TBL] [Abstract][Full Text] [Related]
7. Direct induction onto high-dose long-acting injectable buprenorphine: A case series.
Naren T; Cook J; MacCartney P
Australas Psychiatry; 2024 Jun; 32(3):238-241. PubMed ID: 38444394
[TBL] [Abstract][Full Text] [Related]
8. Transitioning From High-dose Methadone to Buprenorphine Using a Microdosing Approach: Unique Considerations at ASAM Level 3 Facilities.
Anderson C; Cooley R; Patil D
J Addict Med; 2023 Mar-Apr 01; 17(2):241-244. PubMed ID: 36161824
[TBL] [Abstract][Full Text] [Related]
9. Case Series: Limited Opioid Withdrawal With Use of Transdermal Buprenorphine to Bridge to Sublingual Buprenorphine in Hospitalized Patients.
Tang VM; Lam-Shang-Leen J; Brothers TD; Hansen K; Caudarella A; Lamba W; Guimond T
Am J Addict; 2020 Jan; 29(1):73-76. PubMed ID: 31626394
[TBL] [Abstract][Full Text] [Related]
10. Transdermal buprenorphine patch: Potential for role in management of opioid dependence.
Dhawan A; Modak T; Sarkar S
Asian J Psychiatr; 2019 Feb; 40():88-91. PubMed ID: 30772733
[TBL] [Abstract][Full Text] [Related]
11. Rapid microinduction of sublingual buprenorphine from methadone in an outpatient setting: "A case series".
Singh G; Sri Konakanchi J; Betsch B; Thapa A; Sethi R
J Opioid Manag; 2021; 17(7):167-170. PubMed ID: 34520038
[TBL] [Abstract][Full Text] [Related]
12. Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series.
Nielsen S; Bruno R; Degenhardt L; Demirkol A; Lintzeris N
Drug Alcohol Rev; 2017 May; 36(3):311-316. PubMed ID: 27273511
[TBL] [Abstract][Full Text] [Related]
13. Outpatient Microdose Induction with Transdermal Buprenorphine: A Case Series.
Menard S; Jhawar A
Healthcare (Basel); 2022 Jul; 10(7):. PubMed ID: 35885833
[TBL] [Abstract][Full Text] [Related]
14. Transdermal buprenorphine for in-hospital transition from full agonist opioids to sublingual buprenorphine: a retrospective observational cohort study.
Baumgartner K; Salmo E; Liss D; Devgun J; Mullins M; Galati B; Kelly J; Schwarz E
Clin Toxicol (Phila); 2022 Jun; 60(6):688-693. PubMed ID: 35048759
[TBL] [Abstract][Full Text] [Related]
15. A Retrospective Evaluation of Inpatient Transfer from High-Dose Methadone to Buprenorphine Substitution Therapy.
Oretti R
J Subst Abuse Treat; 2015 Oct; 57():102-5. PubMed ID: 26048187
[TBL] [Abstract][Full Text] [Related]
16. Transferring Patients From Methadone to Buprenorphine: The Feasibility and Evaluation of Practice Guidelines.
Lintzeris N; Monds LA; Rivas C; Leung S; Dunlop A; Newcombe D; Walters C; Galea S; White N; Montebello M; Demirkol A; Swanson N; Ali R
J Addict Med; 2018; 12(3):234-240. PubMed ID: 29509558
[TBL] [Abstract][Full Text] [Related]
17. Transdermal buprenorphine to switch patients from higher dose methadone to buprenorphine without severe withdrawal symptoms.
Hess M; Boesch L; Leisinger R; Stohler R
Am J Addict; 2011; 20(5):480-1. PubMed ID: 21838850
[No Abstract] [Full Text] [Related]
18. Cognitive functioning in opioid-dependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates.
Rapeli P; Fabritius C; Kalska H; Alho H
BMC Clin Pharmacol; 2011 Aug; 11():13. PubMed ID: 21854644
[TBL] [Abstract][Full Text] [Related]
19. Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial.
Seval N; Nunez J; Roth P; Schade M; Strong M; Frank CA; Litwin AH; Levin FR; Brady KT; Nunes EV; Springer SA
J Addict Med; 2023 Jul-Aug 01; 17(4):e232-e239. PubMed ID: 37579095
[TBL] [Abstract][Full Text] [Related]
20. Treating opioid use disorder with rapid micro induction technique of sublingual buprenorphine/naloxone in an outpatient setting-a case report.
Martell JP; Konakanchi JS; Sethi R
J Addict Dis; 2022; 40(3):439-443. PubMed ID: 35072589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
